Binocrit: Assessment of quality, safety and efficacy of biopharmaceuticals

EJHP Practice

Volumn 15, Issue 2, 2009, Pages 34-40

  Brockmeyer, Carsten ^a   Seidl, Andreas ^b  

^a Sandoz Biopharmaceuticals   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; ARTICLE; BIOEQUIVALENCE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; HUMAN; IN VIVO STUDY; NONHUMAN; PROTEIN BINDING; PROTEIN STRUCTURE; QUALITY CONTROL;

EID: 70049109465     PISSN: 17819989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kramer I, Tredree R, Vulto AG. Points to consider in the evaluation of biophar- maceuticals. EJHP Practice 2008;14(1):73-76
2. Rentschler Website. Accessed at: http://www.rentschlerbiotechnologie. de/History.13.0.html?&L=1 on May 16, 2008.
3. Villalobos AP, Gunturi SR, Heavner GA. Interaction of poysorbate 80 with ery- thropoietin: a case study in protein-surfactant interactions. Pharm Res. 2005;22:1186-1194
4. Heavner GA, Arakawa T Philo JS, Calmann MA, Labrenz S. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and Eprex". J Pharm Sci. 2007;96(12):3214-3225
5. Schellekens H, Jiskoot W. Erythropoietin-Associated PRCA: Still an Unsolved Mystery. J Immunotoxicol. 2006;3:123-130
6. Binocrit®. EMEA scientific discussion. Accessed at: http://www.emea. europa.eu/humandocs/Humans/EPAR/binocrit/binocrit.htm on May 16, 2008.
7. Binocrit®. Summary of product characteristics.
8. Haag-Weber M, Thyroff-Friesinger U, Vetter A. Longterm efficacy and safety of HX575 (Binocrit/Epoetin Alfa Hexal) in the intravenous (IV) treatment of anaemia in haemodialysis patients (Study INJ-9). NDT Plus 2008;1(Suppl. 2):ii356-7.
9. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. Double-blind, randomzed clinical phase III study to evaluate the efficacy and safety of HX575, a biosimi- lar human recombinant epoetin, for the treatment of chemotherapy associated anaemia in cancer patients (Study INJ-11). Onkologie 2008;31(1):146.
10. European Pharmacopeia 6.0, (06/2007:1316). Published by the European Directorate for the Quality of Medicines & Healthcare. http://www.edqm.eu/ site/The European Pharmacopoeia 6th Edition-681.html
11. Soergel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Comparative pharmacokinetics and pharmacodynamics of HX575 (Binocrit /Epoetin Alfa Hexal) and epoetin alfa (Erypo/Eprex) administered intravenously (IV) to healthy volunteers (Study INJ-5). NDT Plus 2008;1(Suppl. 2):ii357.
12. Soergel F (2), Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Comparative pharmacokinetics and pharmacodynamics of HX575 (Binocrit/ Epoetin Alfa Hexal) and epoetin alfa (Erypo/Eprex) administered subcutaneous- y (SC) to healthy volunteers (Study INJ-12). NDT Plus 2008;1(Suppl. 2):ii356.
13. Soergel F (3), Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Pharmacokinetics and pharmacodynamics of two epoetins: HX575 (Binocrit/ Epoetin Alfa Hexal) and epoetin beta (NeoRecormon) administered subcuta- neously (SC) to healthy volunteers (Study INJ-6). NDT Plus 2008;1(Suppl. 2):ii357.